---
figid: PMC8748807__41398_2021_1778_Fig2_HTML
figtitle: Haloperidol-induced extrapyramidal side effects through the striatal mTOR/S6K
  axis
organisms:
- Saccharomyces cerevisiae
- Vitex negundo
- Picrasma quassioides
- Mus musculus
- Rattus norvegicus
- Homo sapiens
pmcid: PMC8748807
filename: 41398_2021_1778_Fig2_HTML.jpg
figlink: /pmc/articles/PMC8748807/figure/Fig2/
number: F2
caption: Haloperidol, as a pure dopamine 2 receptor (D2R) antagonist, competitively
  blocks post-synaptic D2R in the striatum through an unidentified effector to promote
  mTOR pathway activation. Haloperidol-induced activation of mTORC1, rather than mTORC2,
  acts on its target downstream effectors ribosomal protein S6 kinase (S6K) and phosphorylation
  ribosomal protein (pS6) to promote translation and protein biosynthesis in medium
  spiny neurons (MSNs), alter spine density, and cause extrapyramidal motor disorders.
  The mTOR/S6K axis may translate D2R antagonist (e.g., haloperidol)-mediated signaling
  into extrapyramidal side effects. DA dopamine, D2R dopamine 2 receptor, mTOR the
  mammalian target of rapamycin, mTORC1 the mammalian target of rapamycin complex
  1, MSNs medium spiny neurons, pS6 ribosomal protein S6, S6K ribosomal protein S6
  kinase.
papertitle: 'Mechanistic/mammalian target of rapamycin and side effects of antipsychotics:
  insights into mechanisms and implications for therapy.'
reftext: Chuanjun Zhuo, et al. Transl Psychiatry. 2022;12:13.
year: '2022'
doi: 10.1038/s41398-021-01778-w
journal_title: Translational Psychiatry
journal_nlm_ta: Transl Psychiatry
publisher_name: Nature Publishing Group UK
keywords: Psychiatric disorders | Schizophrenia
automl_pathway: 0.9352772
figid_alias: PMC8748807__F2
figtype: Figure
organisms_ner:
- Mus musculus
redirect_from: /figures/PMC8748807__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8748807__41398_2021_1778_Fig2_HTML.html
  '@type': Dataset
  description: Haloperidol, as a pure dopamine 2 receptor (D2R) antagonist, competitively
    blocks post-synaptic D2R in the striatum through an unidentified effector to promote
    mTOR pathway activation. Haloperidol-induced activation of mTORC1, rather than
    mTORC2, acts on its target downstream effectors ribosomal protein S6 kinase (S6K)
    and phosphorylation ribosomal protein (pS6) to promote translation and protein
    biosynthesis in medium spiny neurons (MSNs), alter spine density, and cause extrapyramidal
    motor disorders. The mTOR/S6K axis may translate D2R antagonist (e.g., haloperidol)-mediated
    signaling into extrapyramidal side effects. DA dopamine, D2R dopamine 2 receptor,
    mTOR the mammalian target of rapamycin, mTORC1 the mammalian target of rapamycin
    complex 1, MSNs medium spiny neurons, pS6 ribosomal protein S6, S6K ribosomal
    protein S6 kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Drd2
  - Mtor
  - Crtc1
  - da
  - Msn
---
